These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11711528)

  • 61. Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment.
    Zannad F
    Am J Cardiol; 1993 Jan; 71(3):34A-39A. PubMed ID: 8422003
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system.
    Brown L; Duce B; Miric G; Sernia C
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S143-8. PubMed ID: 9892155
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Induction of cardiac fibrosis by aldosterone.
    Lijnen P; Petrov V
    J Mol Cell Cardiol; 2000 Jun; 32(6):865-79. PubMed ID: 10888242
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Why does spironolactone improve mortality over and above an ACE inhibitor in chronic heart failure?
    Struthers AD
    Br J Clin Pharmacol; 1999 May; 47(5):479-82. PubMed ID: 10336570
    [No Abstract]   [Full Text] [Related]  

  • 65. [Aldosterone antagonists for all patients with heart failure?].
    Bauersachs J
    MMW Fortschr Med; 2009 Apr; 151(15):33-5. PubMed ID: 19728679
    [No Abstract]   [Full Text] [Related]  

  • 66. Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.
    Nappi JM; Sieg A
    Vasc Health Risk Manag; 2011; 7():353-63. PubMed ID: 21731887
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Aldosterone antagonism in heart failure.
    Richards AM; Nicholls MG
    Lancet; 1999 Sep; 354(9181):789-90. PubMed ID: 10485716
    [No Abstract]   [Full Text] [Related]  

  • 68. Eplerenone enhances cardioprotective effects of standard heart failure therapy through matricellular proteins in hypertensive heart failure.
    Muñoz-Pacheco P; Ortega-Hernández A; Caro-Vadillo A; Casanueva-Eliceiry S; Aragoncillo P; Egido J; Fernández-Cruz A; Gómez-Garre D
    J Hypertens; 2013 Nov; 31(11):2309-18; discussion 2319. PubMed ID: 24077250
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Aldosterone and myocardial fibrosis in heart failure.
    Brilla CG
    Herz; 2000 May; 25(3):299-306. PubMed ID: 10904856
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ACE inhibitors and mineralocorticoid receptor blockade in patients with congestive heart failure.
    Funder JW
    Curr Diab Rep; 2005 Feb; 5(1):36-40. PubMed ID: 15663915
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Spironolactone improves the arrhythmogenic substrate in heart failure by preventing ventricular electrical activation delays associated with myocardial interstitial fibrosis and inflammation.
    Esposito CT; Varahan S; Jeyaraj D; Lu Y; Stambler BS
    J Cardiovasc Electrophysiol; 2013 Jul; 24(7):806-12. PubMed ID: 23489714
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Diuretic therapy in congestive heart failure--new views on spironolactone therapy].
    Haller C
    Ther Umsch; 2000 Jun; 57(6):374-9. PubMed ID: 10894022
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The SEISICAT study: a pilot study assessing efficacy and safety of spironolactone in cats with congestive heart failure secondary to cardiomyopathy.
    James R; Guillot E; Garelli-Paar C; Huxley J; Grassi V; Cobb M
    J Vet Cardiol; 2018 Feb; 20(1):1-12. PubMed ID: 29277469
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aldosterone as a target in congestive heart failure.
    Rajagopalan S; Pitt B
    Med Clin North Am; 2003 Mar; 87(2):441-57. PubMed ID: 12693733
    [TBL] [Abstract][Full Text] [Related]  

  • 75. [Aldosterone antagonist therapy for chronic heart failure].
    Yamamoto T; Yano M
    Nihon Naika Gakkai Zasshi; 2005 Feb; 94(2):262-9. PubMed ID: 15768590
    [No Abstract]   [Full Text] [Related]  

  • 76. Integrating traditional and emerging treatment options in heart failure.
    Nolan PE
    Am J Health Syst Pharm; 2004 May; 61 Suppl 2():S14-22. PubMed ID: 15160834
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Effects of spironolactone on endothelial function, vascular angiotensin converting enzyme activity, and other prognostic markers in patients with mild heart failure already taking optimal treatment.
    Macdonald JE; Kennedy N; Struthers AD
    Heart; 2004 Jul; 90(7):765-70. PubMed ID: 15201246
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [Decrease in mortality on spironolactone being added to the conventional treatment of heart failure].
    Soto Alvarez J
    Aten Primaria; 2000 Mar; 25(4):282-4. PubMed ID: 10795447
    [No Abstract]   [Full Text] [Related]  

  • 79. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure.
    Glick HA; Orzol SM; Tooley JF; Remme WJ; Sasayama S; Pitt B
    Cardiovasc Drugs Ther; 2002 Jan; 16(1):53-9. PubMed ID: 12085979
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Do diuretics and aldosterone receptor antagonists improve ventricular remodeling?
    Pitt B
    J Card Fail; 2002 Dec; 8(6 Suppl):S491-3. PubMed ID: 12555163
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.